Thursday, July 31, 2014

WB starts Tandem Diabetes Care at outperform

WB starts Tandem Diabetes Care at outperform

July 15, 2014 by · Leave a Comment 

Tweet William Blair has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with an “outperform” rating and “aggressive growth” profile. The stock closed at $13.37 on Tuesday. Tandem Diabetes makes and markets a durable, tube-based insulin pump with an easy to train and use touch screen user interface to treat Type 1 and potentially Type 2 […]

HCW starts Transition Therapeutics at buy

HCW starts Transition Therapeutics at buy

July 15, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) with a “buy” rating and 12-month price target of $10. The stock closed at $6.58 on Monday. Transition has two molecules in clinical evaluation in three indications. ELND005 is a small molecule in Phase 2 for Alzheimer’s disease (AD) associated agitation, and Down syndrome […]

Pivotal’s fight against fat gains media exposure

Pivotal’s fight against fat gains media exposure

June 25, 2014 by · Leave a Comment 

Tweet The latest issue of Bio Business magazine includes an article about the global obesity epidemic that highlights the efforts of Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to tackle the problem by focusing on the development of Omega-3 therapies and diagnostics. “The consequences of an Omega-3 deficiency could be obesity, diabetes, elevated triglycerides, high cholesterol and coronary heart […]

Transition, Lilly begin Phase 2 diabetes study

Transition, Lilly begin Phase 2 diabetes study

May 15, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) announced the dosing of the first patient in a Phase 2 clinical study of TT-401, a drug candidate for the treatment of Type 2 diabetes. The study is expected to enroll up to 375 Type 2 diabetes subjects and will be performed by Transition’s development partner, Eli Lilly (NYSE:LLY). The objectives […]

Aurinia to begin lupus nephritis trial at end of April

Aurinia to begin lupus nephritis trial at end of April

April 15, 2014 by · Leave a Comment 

Tweet Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient at the end of April in a Phase 2b clinical trial with its voclosporin immunosuppressant in combination with CellCept®, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “We are now well capitalized […]

Transition moves into late-stage drug development

Transition moves into late-stage drug development

March 18, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate, ELND005. “We’re maybe a year away from seeing the results of ELND005 in two Phase 2 trials for the treatment of agitation/aggression in patients with mild-to-severe Alzheimer’s disease (AD), and as an […]

Boston Therapeutics planning pivotal trial

Boston Therapeutics planning pivotal trial

December 10, 2013 by · Leave a Comment 

Tweet Boston Therapeutics (OTCQB:BTHE) hopes to begin a pivotal Phase 3 trial, by the second or third quarter of 2014, of a chewable tablet that is designed to be taken before meals to reduce post-meal elevation of blood glucose in Type 2 diabetics. “Our PAZ320 drug is a potential adjunct to metformin in patients living […]

Stifel starts Tandem Diabetes at buy

Stifel starts Tandem Diabetes at buy

December 9, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=h6pWELJ4nYs’]

Tweet Stifel Nicolas has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with a “buy” rating and $30 price target, saying the company appears poised for dramatic growth with what “we view as a compelling differentiated platform technology, and a highly visible pipeline in the large, growing, and arguably under-penetrated insulin pump market.” Shares of Tandem […]

Aurinia readies Phase 2b trial in lupus nephritis

Aurinia readies Phase 2b trial in lupus nephritis

November 19, 2013 by · Leave a Comment 

Tweet Aurinia Pharmaceuticals (TSX-V:AUP) is preparing to begin a Phase 2b clinical trial in the first quarter of 2014 with its voclosporin immunosuppressant in combination with CellCept, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “The core of our management team executed the Aspreva Lupus Management Study, which […]

In conversation with Kelly Close

In conversation with Kelly Close

September 24, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=TQmt739ynr4′]

Tweet As president and founder of Close Concerns, a healthcare information firm focused on diabetes and obesity, Kelly Close says her passion comes from her extensive professional work as well as her personal experience, contracting Type 1 diabetes 25 years ago. Prior to starting Close Concerns, she worked in the financial sector, including stints as […]

Next Page »

Email Newsletters with Constant Contact
Google+